|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunization with melanoma antigens conjugated to antibodies (Abs) specific for mouse CD169 efficiently induced gp100 and Trp2-specific T cell responses in mice.
|
30764534 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the TRP2-mRNA/α-GalCer-based multi-LP vaccine induced a significant therapeutic effect against a highly malignant B16-F10 melanoma tumor.
|
31460428 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that mannosylated Trp-2 and MPLA-loaded PBAE nano-vaccines can target and mature DCs, consequently boosting antigen-specific cytotoxic T lymphocyte activity against melanoma.
|
31593795 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, the TRP2-mRNA/α-GalCer-based multi-LP vaccine induced a significant therapeutic effect against a highly malignant B16-F10 melanoma tumor.
|
31460428 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combining gene transfer of the melanoma-specific TRP2-TCR with Tet-IL-12 engineering revealed that temporal induction of IL-12 was essential to inhibit the growth of B16F10 melanoma tumors.
|
30723575 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An indoleamine 2, 3-dioxygenase siRNA nanoparticle-coated and Trp2-displayed recombinant yeast vaccine inhibits melanoma tumor growth in mice.
|
29355622 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using melanoma as the model cancer and Tyrosinase-related protein 2 (Trp2) peptide as the model antigen, we demonstrated that dispersion-stable LDH-based vaccine induced stronger cytotoxic T-lymphocyte (CTL) responses and significantly inhibited tumor growth in comparison with aggregated LDH-based vaccine.
|
29778982 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used two mouse models of melanoma termed B16.OVA and B16-F10 for testing the efficacy of OVA SIINFEKL-peptide-coated viruses and gp100-Trp2-peptide-coated viruses, respectively, and show that by coating the viral envelope with therapeutic peptides, the anti-tumor immunity and the number of tumor-specific CD8<sup>+</sup> T cells in the tumor microenvironment can be significantly enhanced.
|
30005865 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the combination treatment of RGP and tyrosinase-related protein 2 (TRP2) peptide, a melanoma self-antigen, protected mice from melanoma challenge.
|
30282011 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LCP mRNA vaccine encoding TRP2 elicited a robust antigen-specific cytotoxic T cell response and a humoral immune response in a C57BL/6 mouse model of B16F10 melanoma.
|
29249397 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We used two mouse models of melanoma termed B16.OVA and B16-F10 for testing the efficacy of OVA SIINFEKL-peptide-coated viruses and gp100-Trp2-peptide-coated viruses, respectively, and show that by coating the viral envelope with therapeutic peptides, the anti-tumor immunity and the number of tumor-specific CD8<sup>+</sup> T cells in the tumor microenvironment can be significantly enhanced.
|
30005865 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By investigating compound FcγR-deficient mouse strains and by using immune cell type-specific cell ablation we show that the IgG antibody-mediated tumor protection elicited by MCMV-TRP2 mainly depends on FcγRI expression on macrophages, whereas FcγRIV plays only a modest role.
|
30034625 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ImmunoMap analysis of the CD8 T-cell response to self-antigen (K<sup>b</sup>-TRP2) or to a model foreign antigen (K<sup>b</sup>-SIY) in naïve and tumor-bearing B6 mice showed differences in the T-cell repertoire of self- versus foreign antigen-specific responses, potentially reflecting immune pressure by the tumor, and also detected lymphoid organ-specific differences in TCR repertoires.
|
29263161 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An indoleamine 2, 3-dioxygenase siRNA nanoparticle-coated and Trp2-displayed recombinant yeast vaccine inhibits melanoma tumor growth in mice.
|
29355622 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using melanoma as the model cancer and Tyrosinase-related protein 2 (Trp2) peptide as the model antigen, we demonstrated that dispersion-stable LDH-based vaccine induced stronger cytotoxic T-lymphocyte (CTL) responses and significantly inhibited tumor growth in comparison with aggregated LDH-based vaccine.
|
29778982 |
2018 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment of B16F10 melanoma tumors with lipid nanoparticles containing mRNA coding for the tumor-associated antigens gp100 and TRP2 resulted in tumor shrinkage and extended the overall survival of the treated mice.
|
28273716 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SLA individually or mixed with uncharged glyolipid (lactosylarchaeol, LA) constituted efficacious carrier vesicles for entrapped antigens (ovalbumin or melanoma associated tyrosinase-related protein 2 [TRP-2]) and induction of strong cell-mediated responses in mice and protection against subsequent B16 melanoma tumor challenge.
|
28537465 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously developed a potent mannose-modified lipid calcium phosphate (LCP) nanoparticle (NP)-based Trp2 vaccine for melanoma therapy, but because this vaccine can induce a potent anti-tumor immune response only during the early stages of melanoma, poor tumor growth inhibition has been observed in more advanced melanoma models, likely due to the development of an immune-suppressive tumor microenvironment (TME).
|
27863995 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, therapeutic vaccination with pTRP2 and shIκBα delayed the growth of B16F10 melanoma subcutaneous tumors.
|
28666759 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.
|
29296525 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of B16F10 melanoma tumors with lipid nanoparticles containing mRNA coding for the tumor-associated antigens gp100 and TRP2 resulted in tumor shrinkage and extended the overall survival of the treated mice.
|
28273716 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed the development of the TRP2-specific iPSC-CD8<sup>+</sup> T cells that responded to Ag stimulation and infiltrated into melanoma tissues, significantly inhibited the tumor growth, and improved the survival of the tumor-bearing mice.
|
28811978 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we introduce a versatile nanovaccine of liposomes-coated gold nanocages (Lipos-AuNCs) modified with DCs specific antibody aCD11c for targeted delivery of adjuvant MPLA and melanoma antigen peptide TRP2 to promote the activation and maturation of DCs, and enhance tumor specific T lymphocytes responses.
|
28992509 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The in vivo study showed that mice having received TRP2 loaded implants had delayed tumour growth for 3days compared to groups having received no TRP2.
|
28104440 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A structural and functional relationship between DCT and CAV1 is first presented here in two human amelanotic melanoma cell lines, derived from vertical growth phase (MelJuSo) and metastatic (SKMel28) melanomas.
|
27053106 |
2016 |